-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gaithersburg, Maryland, September 24, 2021/PRNewswire/ - Novavax, Inc.
The trial compares NanoFlu with the leading quadrivalent influenza vaccine licensed in the United States, assessing its immunogenicity and safety in the elderly
Stanley C.
Novavax previously announced that NanoFlu has achieved the primary endpoint of the trial, demonstrating the non-inferior immunogenicity of all four influenza virus strains in the vaccine compared with the Fluzone® tetravalent vaccine, and at the same time showing the homology of the Fluzone tetravalent vaccine.
In addition, NanoFlu showed effective induction of CD4+ T cells against the multifunctional antigen-specific CD4+ T cells of the A/H3N2 and B/Victoria strains.
You can visit this article "Comparing the safety and immunogenicity of a novel nanoparticle influenza vaccine using Matrix-M adjuvant and a quadrivalent seasonal influenza vaccine in the elderly: Phase 3 randomized controlled trial" paper here
About NanoFlu™
NanoFlu™ is a quadrivalent recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced in Novavax's SF9 insect cell baculovirus system
About Matrix-M™ adjuvant
Novavax's patented Matrix-M™ adjuvant based on saponin can stimulate antigen-presenting cells to enter the injection site, enhance antigen presentation in local lymph nodes, thereby enhancing immune response, and has shown a strong and well-tolerated effect
About Novavax
Novavax, Inc.
Forward-looking statements
This article discusses the future of Novavax, its operational plans and prospects, the continuous development of NanoFlu™ and its partnership, as well as other Novavax vaccine candidate products, the efficacy, safety, and expected use of vaccines and expected use of our candidate products, the timing of clinical trial results, and Statements regarding the potential of the NanoFlu and NVX-CoV 2373 combined vaccine to improve the efficiency of the healthcare system and achieve a high level of protection against new coronary pneumonia and influenza are forward-looking statements
